Home » Stocks » Calliditas Therapeutics

Calliditas Therapeutics AB (CALT)

Stock Price: $22.22 USD -1.39 (-5.89%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 532.60M
Revenue (ttm) 19.87M
Net Income (ttm) -3.50M
Shares Out 23.97M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $22.22
Previous Close $23.61
Change ($) -1.39
Change (%) -5.89%
Day's Open 23.50
Day's Range 21.16 - 23.59
Day's Volume 18,030
52-Week Range 19.00 - 24.97

More Stats

Market Cap 532.60M
Enterprise Value 451.57M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 23.97M
Float 22.72M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -0.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 12,445
Short Ratio 0.05
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 26.80
PB Ratio 6.07
Revenue 19.87M
Operating Income -3.01M
Net Income -3.50M
Free Cash Flow -7.65M
Net Cash 81.03M
Net Cash / Share 3.38
Gross Margin 100.00%
Operating Margin -15.16%
Profit Margin -17.60%
FCF Margin -38.48%
ROA -5.24%
ROE -8.27%
ROIC 938.10%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions SEK.

Financial Overview

Gross Profit185-
Operating Income-28.02-132
Net Income-32.58-132
Shares Outstanding46.30-
Earnings Per Share-1.76-10.18
Operating Cash Flow-71.01-128
Capital Expenditures-0.12-
Free Cash Flow-71.13-128
Cash & Equivalents754646
Net Cash / Debt754646
Book Value788618
Numbers in millions SEK, except per-share numbers.

Company Profile

Company Details

Full Name Calliditas Therapeutics AB
Country Sweden
Employees 17
CEO Renée Julie Elisabet Aguiar-Lucander

Stock Information

Ticker Symbol CALT
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: CALT
IPO Date June 5, 2020


Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.